Selected publications:
[1] Jeleff M, et al. Effectiveness of digital health interventions in influencing the primary prevention of noncommunicable diseases: Protocol for an umbrella review. BMJ Open 2026; 16(1):e110671. DOI: 10.1136/bmjopen-2025-110671
[2] Bicher M, (…), Jeleff M, Popper N, Rippinger C, Urach C, Zauner G, Zechmeister M, Zimmermann C. Impactevaluierung von Priorisierten Impfungen (Report). TU Wien 2025. DOI: 10.48436/sqvcq-qwg65
[3] Erber AC, (…), E, Jeleff M, Maguire BJ, Nyaoke B, Regensburger S, Srambickal A, Strub-Wourgaft N, Tirado-S.nchez A, Weichselberger T, Fahal AH, Zijlstra EE, Gu.rin PJ. A systematic review of the clinical study landscape for eumycetoma, 1990-2024. Manuscript under review at BMJ Global Health.
[4] Jeleff M, et al. Cancer risk factors and access to cancer prevention services for people experiencing homelessness. Lancet Public Health 2024; 9(2):e128-e146. DOI: 10.1016/s2468-2667(23)00298-0
[5] Jeleff M, Haddad C, Kutalek R. Between superimposition and local initiatives: Making sense of implementation gaps’ as a governance problem of antimicrobial resistance. SSM Qualitative Research in Health 2023; 4:100332. DOI: 10.1016/j.ssmqr.2023.100332
[6] Schiffler T, Jeleff M, Gil-Salmer.n A, Yang L, Haider S, Schuch FB, Grabovac I. Cancer risk factors and access to cancer prevention services for people experiencing homelessness: a scoping review protocol. BMJ Open 2023; 13(8):e074710. DOI: 10.1136/bmjopen-2023-074710
[7] Jeleff M, Lehner L, Giles-Vernick T, Dückers MA, Napier D, Jirovsky E, Kutalek R. Vulnerability and One Health assessment approaches for infectious threats from a social science perspective: A systematic scoping review. Lancet Planetary Health 2022; 6(8):e682-e693. DOI: 10.1016/s2542-5196(22)00097-3
[8] Jeleff M, et al. Occupational challenges of health care workers during the COVID-19 pandemic: a qualitative study. BMJ Open 2022; 12(3):e054516. DOI: 10.1136/bmjopen-2021-054516
[9] Erber AC, Wagner A, Karachaliou M, Jeleff M, (…), Papantoniou K. The association of time of day of ChAdOx1 nCoV-19 vaccine administration with SARS-CoV-2 anti-spike IgG antibody levels: an exploratory observational study. J Biol Rhythms 2023; 38(1):98-108. DOI: 10.1177/07487304221132355
[10] Jeleff M, et al. Vulnerability assessment tools for infectious threats and antimicrobial resistance: a scoping review protocol. BMJ Open 2019; 9(11):e031944. DOI: 10.1136/bmjopen-2019-031944